Immunoglobulin G1, anti-(human/Macaca fascicularis/Macaca mulatta killer cell lectin-like receptor KLRD1) (human monoclonal DR-01 ?1-chain), disulfide with human monoclonal DR-01 ?-chain, dimer
Aggressive NK Cell Leukemia
Dren Biomonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Aggressive NK Cell Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide The Affiliated Hospital of Xuzhou Medical University | Phase 2 | B |
Anti-Thymoglobulin, Rabbit St. Jude Children's Research Hospital | Phase 2 | CCC |
Mesna St. Jude Children's Research Hospital | Phase 2 | CCC |
Thiotepa St. Jude Children's Research Hospital | Phase 2 | CCC |
Anti-Cd56 Car T The Affiliated Hospital of Xuzhou Medical University | Phase 2 | CCC |
View all 21 →
Same molecule, other indications
Immunoglobulin G1, anti-(human/Macaca fascicularis/Macaca mulatta killer cell lectin-like receptor KLRD1) (human monoclonal DR-01 ?1-chain), disulfide with human monoclonal DR-01 ?-chain, dimer is also rated in:
primary cutaneous aggressive epidermotropic CD8+ T-cell lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →